casirivimab/imdevimab

Action and Spectrum

Drug Interaction

Adverse Reaction

Frequency defined:  

>10% 

Subcutaneous- reaction at the site of injection 

1-10% 

IV-reaction at the site of infusion 

Frequently not defined: 

Dyspnea 

Vomiting 

Intestinal obstruction 

Hyperglycemia 

Pneumonia 

Nausea 

Anaphylactic reactions 

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pregnancy consideration: Insufficient data is available 

Lactation: Excretion of the drug in human breast milk is unknown 

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women 
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh the risks over benefits. These category drugs should be prohibited for pregnant women. 
• Category N: No data is available for the drug under this category. 

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name: Casirivimab/imdevimab 

Pronounced: (kas i RIV i mab & im DEV i mab)  

Why do we use Casirivimab/imdevimab? 

The SARS-CoV-2 virus-based coronavirus disease 2019 (COVID-19) is treated and prevented with it.